← Back to Search

Semaglutide for Obesity

N/A
Recruiting
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, midpoint (8-12 weeks), end of study (24 + 2 weeks)
Awards & highlights
No Placebo-Only Group

Summary

This study aims to assess the impact of GLP-1 receptor agonists, semaglutide and tirzepatide, on food cravings and diet quality in individuals with overweight or obesity. Over 24 weeks, up to 150 adult participants will be monitored using questionnaires and dietary records at 0, 12, and 24 weeks to measure changes in diet quality, disordered eating, food cravings, and hunger. This research, conducted with Seen Medical Group at Knownwell Health Clinic, seeks to fill the gap in literature on the dietary quality effects of GLP-1RAs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, midpoint (8-12 weeks), end of study (24 + 2 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, midpoint (8-12 weeks), end of study (24 + 2 weeks) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Food Craving Score
Secondary study objectives
Change in USDA Healthy Eating Index-2015 (HEI) Score
Other study objectives
Changes in body fat percentage
Changes in resting metabolic rate (RMR)
Changes in segmental skeletal muscle mass (lbs)
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: TirzepatideExperimental Treatment4 Interventions
eligible patients who are prescribed tirzepatide for their obesity-management
Group II: SemaglutideExperimental Treatment4 Interventions
eligible patients who are prescribed semaglutide for their obesity-management
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Surveys
2020
Completed Phase 1
~11340

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
936 Previous Clinical Trials
4,719,579 Total Patients Enrolled
30 Trials studying Obesity
33,524 Patients Enrolled for Obesity
KnownwellUNKNOWN
~100 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top